¼¼°èÀÇ Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå : »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, À¯Çüº°, ÀûÀÀÁõº°, ·çÆ®º°, À¯Åë ä³Îº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Route, By Distribution Channel, By Region and Competition, 2020-2030F
»óǰÄÚµå : 1698010
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 181 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,575,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 114¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â±îÁö ¿¹Ãø±â°£ µ¿¾È ¿¬Æò±Õ 12.86% ¼ºÀåÇÏ¿© 236¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦(DAA) ½ÃÀåÀº ¹ÙÀÌ·¯½º °¨¿°, ƯÈ÷ CÇü °£¿°ÀÇ È®»êÀ¸·Î ÀÎÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ƯÁ¤ ¹ÙÀÌ·¯½º ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î ÇÏ¿© º¹Á¦¸¦ ¾ïÁ¦Çϱ⠶§¹®¿¡ ¸Å¿ì È¿°úÀûÀÌ°í ³»¾à¼ºÀÌ ÁÁÀº Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀǾàǰÀÇ ¹ßÀüÀ¸·Î È¿´ÉÀÌ Çâ»óµÇ°í Ä¡·á ±â°£ÀÌ ´ÜÃàµÈ Â÷¼¼´ë DAA°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·áÁø°ú Á¤ºÎ°¡ CÇü °£¿° ÅðÄ¡ ÇÁ·Î±×·¥À» ¿ì¼±¼øÀ§¿¡ µÎ¸é¼­ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. º´¿ë¿ä¹ýÀÇ µµÀÔÀº Ä¡·á °á°ú¸¦ ´õ¿í Çâ»ó½Ã۰í, ¾àÁ¦ ³»¼º À§ÇèÀ» ÁÙÀ̸ç, Áö¼ÓÀû ¹ÙÀÌ·¯½ºÇÐÀû ¹ÝÀÀ(SVR)À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ½ÅÈï±¹¿¡¼­ÀÇ Áø´Ü °Ë»ç ¹× Ä¡·á Á¢±Ù¼º È®´ë´Â ½ÃÀå È®´ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 114¾ï 1,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 236¾ï 1,000¸¸ ´Þ·¯
CAGR : 2025-2030³â 12.86%
±Þ¼ºÀå ºÎ¹® NS3/4 A ÇÁ·ÎÅ×¾ÆÁ¦
ÃÖ´ë ½ÃÀå ºÏ¹Ì

Á¶±â Áø´Ü ¹× Á¶±â Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ºñ¿µ¸® ´ÜüÀÇ Áö¿øÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Ç×¹ÙÀÌ·¯½ºÁ¦ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϸ鼭 ¾ÈÀü¼ºÀÌ °³¼±µÈ Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ßÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀº ´õ ³ôÀº Ä¡·á ¼º°ø·üÀ» º¸ÀåÇϴ ǥÀû Ç×¹ÙÀÌ·¯½º ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¹× À¯ÀüÀÚ ¿¬±¸ÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î Á¦¾àȸ»çµéÀº º¸´Ù Á¤¹ÐÇÏ°í °­·ÂÇÑ DAA¸¦ ¼³°èÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÁÖ»ç Ä¡·áº¸´Ù °æ±¸ Ä¡·áÀÇ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ȯÀÚµéÀÇ ¼øÀÀµµ°¡ Çâ»óµÇ¾î DAA°¡ Ç×¹ÙÀÌ·¯½º Ä¡·á Àü·«¿¡¼­ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü°ú Á¦¾à»çÀÇ °øµ¿¿¬±¸´Â ÀǾàǰ °³¹ßÀ» ÃËÁøÇϰí Â÷¼¼´ë DAAsÀÇ °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë¿Í °¢±¹ÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥Àº ½ÃÀå ±â¾÷µé¿¡°Ô ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ÁøÀü¿¡µµ ºÒ±¸Çϰí, ½ÃÀåÀº ³ôÀº Ä¡·á ºñ¿ë°ú °ü·ÃµÈ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, Àú¼Òµæ Áö¿ªÀÇ È¯Àڵ鿡°Ô Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. ¾àÁ¦ ³»¼º ¹ÙÀÌ·¯½º ±ÕÁÖÀÇ ÃâÇöÀÌ ¿ì·ÁµÇ°í ÀÖÀ¸¸ç, º¸´Ù È¿°úÀûÀÎ Á¦Á¦ °³¹ßÀ» À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°¡ ÇÊ¿äÇÕ´Ï´Ù. ±ÔÁ¦ À庮°ú ½Å±Ô DAAÀÇ ½ÂÀÎ ÀýÂ÷¿¡ ½Ã°£ÀÌ ¿À·¡ °É¸®±â ¶§¹®¿¡ ½ÃÀå ÁøÀÔÀÌ Áö¿¬µÇ¾î Çõ½Å Áֱ⿡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀϺΠÁö¿ª¿¡¼­´Â È¿°úÀûÀÎ Ç×¹ÙÀÌ·¯½º Ä¡·áÁ¦ÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀνÄÀÌ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ äÅ÷üÀÌ µÐÈ­µÇ°í ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀÇ Á¸Àç´Â ½ÃÀå °æÀïÀ» ½ÉÈ­½ÃÄÑ °¡°Ý Àü·«À» ¾Ð¹ÚÇϰí ÀÖ½À´Ï´Ù. Àü·«Àû °¡°Ý Ã¥Á¤ ¸ðµ¨, ³»¼º °ü¸® Á¶»ç, ¼¼°è Ä¡·á º¸±Þ Ȱµ¿ °­È­¸¦ ÅëÇØ ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» À¯ÁöÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

³ôÀº È¿°ú¿Í Ä¡·áÀ² Çâ»ó

ÁÖ¿ä ½ÃÀå À̽´

³ôÀº Ä¡·áºñ

ÁÖ¿ä ½ÃÀå µ¿Çâ

ÀûÀÀÁõ È®´ë

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á÷Á¢ ÀÛ¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå ¸®¼­Ä¡»ç¿¡ ´ëÇØ & ¸éÃ¥»çÇ×

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Direct-acting Antiviral Drug Market was valued at USD 11.41 Billion in 2024 and is expected to reach USD 23.61 Billion in the forecast period with a CAGR of 12.86% through 2030. The global direct-acting antiviral (DAA) drug market is expanding due to the increasing prevalence of viral infections, particularly hepatitis C. These drugs target specific viral proteins to inhibit replication, offering a highly effective and well-tolerated treatment option. Pharmaceutical advancements have led to the development of next-generation DAAs with improved efficacy and shorter treatment durations. The market is witnessing significant growth as healthcare providers and governments prioritize hepatitis C elimination programs. The introduction of combination therapies has further enhanced treatment outcomes, reducing the risk of drug resistance and increasing sustained virologic response (SVR) rates. Expanding access to diagnostic testing and treatment in developing countries is playing a crucial role in market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.41 Billion
Market Size 2030USD 23.61 Billion
CAGR 2025-203012.86%
Fastest Growing SegmentNS3/4 A Protease
Largest MarketNorth America

The market is benefiting from increasing awareness of early diagnosis and treatment, supported by government initiatives and non-profit organizations. Rising investments in antiviral drug research are fostering the development of innovative therapies with improved safety profiles. The shift toward personalized medicine is influencing the demand for targeted antiviral therapies, ensuring higher treatment success rates. Breakthroughs in biotechnology and genetic research are enabling pharmaceutical companies to design more precise and potent DAAs. The growing preference for oral therapies over injectable treatments is driving patient adherence, making DAAs a preferred choice in antiviral treatment strategies. Collaborations between research institutions and pharmaceutical firms are expediting drug development, leading to a robust pipeline of next-generation DAAs. Expanding healthcare infrastructure and favorable reimbursement policies in various countries are creating opportunities for market players.

Despite advancements, the market faces challenges related to high treatment costs, limiting accessibility for patients in low-income regions. The emergence of drug-resistant viral strains is a growing concern, requiring continuous research to develop more effective formulations. Regulatory hurdles and lengthy approval processes for new DAAs can delay market entry, impacting innovation cycles. Limited awareness in certain regions about the availability of effective antiviral treatments is slowing adoption rates. The presence of generic alternatives is intensifying market competition, putting pressure on pricing strategies. Addressing these challenges through strategic pricing models, research in resistance management, and increased global treatment outreach will be essential for sustaining market growth.

Key Market Drivers

High Efficacy and Improved Cure Rates

In recent years, the global pharmaceutical landscape has witnessed a transformative shift in the treatment of viral infections, particularly hepatitis C, due to the advent of direct-acting antiviral drugs (DAAs). These innovative medications have demonstrated exceptional efficacy, with cure rates exceeding 95%, redefining the approach to managing viral diseases.

The high efficacy of DAAs translates into significantly improved patient outcomes. For instance, a study published in JAMA Network Open reported that among patients treated with DAAs, 97.3% achieved sustained virologic response (SVR), indicating a cure. Successful DAA therapy not only clears the virus but also halts disease progression, reducing risks of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Beyond individual benefits, DAAs contribute to public health by reducing viral transmission. Effective treatment decreases viral load, thereby lowering the likelihood of spreading infections such as hepatitis B and C, which are transmitted through routes like blood contact and sexual intercourse. The World Health Organization highlights that DAAs can cure over 95% of hepatitis C cases, yet access to diagnosis and treatment remains limited globally.

DAAs also offer shorter treatment durations compared to traditional interferon-based therapies. While older regimens required treatment courses of up to 48 weeks, DAA therapies typically range from 8 to 12 weeks, enhancing patient compliance and reducing healthcare burdens. Furthermore, DAAs are associated with improved tolerability and fewer severe side effects, encouraging patients to complete their treatment regimens.

The success of DAAs has instilled confidence among patients and healthcare providers. For example, the U.S. Department of Health and Human Services notes that new hepatitis C treatments can cure approximately 95% of patients, significantly decreasing the likelihood of severe liver complications and reducing overall healthcare costs. This underscores the importance of expanding access to these life-saving therapies to achieve broader public health benefits.

Key Market Challenges

High Treatment Costs

One of the most significant challenges is the high cost of direct-acting antiviral drugs. While these medications are highly effective, their price tags can be prohibitive for many patients, especially in low- and middle-income countries. Striking a balance between recouping research and development costs and ensuring affordable access is a persistent challenge.

Key Market Trends

Expanded Indications

One significant trend in the DAA market is the exploration of expanded indications. While DAAs have been predominantly used to treat hepatitis C and B, researchers are investigating their efficacy against other viral infections. This could lead to the development of new DAA therapies targeting a broader range of viruses.

Key Market Players

Report Scope:

In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct-acting Antiviral Drug Market, By Type:

Direct-acting Antiviral Drug Market, By Indication:

Direct-acting Antiviral Drug Market, By Route:

Direct-acting Antiviral Drug Market, By Distribution Channel:

Direct-acting Antiviral Drug Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.

Available Customizations:

Global Direct-acting Antiviral Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Direct-acting Antiviral Drug Market Outlook

6. North America Direct-acting Antiviral Drug Market Outlook

7. Europe Direct-acting Antiviral Drug Market Outlook

8. Asia-Pacific Direct-acting Antiviral Drug Market Outlook

9. South America Direct-acting Antiviral Drug Market Outlook

10. Middle East and Africa Direct-acting Antiviral Drug Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porter's Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â